Clinico-pathological implications of the 2022 WHO Renal cell carcinoma classification
The fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO “Blue Book”), published in 2022, contains significant revisions upon the previous 2016 version regarding Renal Cell Carcinoma (RCC) (Figure 1).[1,2] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 8, 2023 Category: Cancer & Oncology Authors: Rizzo Mimma, Cali ò Anna, Brunelli Matteo, Pezzicoli Gaetano, Ganini Carlo, Martignoni Guido, Porta Camillo Tags: Hot Topic Source Type: research
Acquired resistance mechanisms to osimertinib: the constant battle
Lung cancer is the leading cause of cancer-related mortality worldwide, mainly due to poor overall survival and late-stage initial diagnosis [1]. Non-small-cell lung cancer (NSCLC) represents nearly 85% of lung cancers [2]. Recently, detectable driver mutations have revolutionized lung cancer treatment with the emergence of targeted therapy as a novel therapeutic strategy that has widely improved lung cancer prognosis, especially in metastatic patients [2]. Adenocarcinoma, the most common subtype of NSCLC, is where most mutations occur. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 6, 2023 Category: Cancer & Oncology Authors: Ziad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, Samir Hachem, Roland Eid, Hampig Raphael Kourie, David Planchard Tags: Anti-tumour Treatment Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 30, 2023 Category: Cancer & Oncology Source Type: research
Immunotherapy-based combinations in metastatic NSCLC
Since the first approval of immunotherapy in 2015 by the U.S. FDA, the advent of immunotherapy has changed the treatment paradigm of metastatic non-small cell lung cancer (mNSCLC).[1] With increased lung cancer screening efforts, and approvals for use of anti-Programmed Death-1 (PD-1)/ Programmed Death-Ligand 1 (PD-L1) antibodies in the unresectable locally advanced disease and the perioperative setting, the use of immunotherapy will continue to increase in the coming decade.[2,3] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 26, 2023 Category: Cancer & Oncology Authors: Aakash Desai, Solange Peters Tags: New Drugs Source Type: research
The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers
Gynecologic malignancies, particularly ovarian, cervical, and uterine cancers, represent a substantial healthcare burden in women. In the United States alone, nearly 100,000 new cases of gynecologic malignancies and 30,000 related deaths have been estimated for 2022 [1 –3]. Among all cases diagnosed between 2012 and 2018, the 5-year survival rate for patients with metastatic tumors was approximately 31% for ovarian cancer, 17% for cervical cancer, and 18% for uterine cancer [1–3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 19, 2023 Category: Cancer & Oncology Authors: Anthony Tolcher, Erika Hamilton, Robert L. Coleman Tags: Anti-tumour Treatment Source Type: research
Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy
Overall survival (OS) is the most relevant efficacy endpoint in clinical cancer research. However, implementing OS as a primary endpoint in confirmatory trials can be challenging due to the longer follow-up required, larger sample size, cost, and the potential delay of drug approval. Surrogate endpoints [1-3] are valid alternatives to OS for many regulatory agencies, including the US Food and Drug Administration (FDA), for their ease and speed of measurement [4,5]. Indeed, drug approval through regular pathways was based on surrogate endpoints in 52-68% of the cases, while the accelerated approval path adopts surrogate end...
Source: Cancer Treatment Reviews - March 17, 2023 Category: Cancer & Oncology Authors: Guillermo Villacampa, Pablo Cresta Morgado, Victor Navarro, Cristina Viaplana, Rodrigo Dienstmann Tags: Systematic or Meta-analysis Studies Source Type: research
Secondary prevention and treatment innovation of early stage Non-Small Cell Lung Cancer: impact on diagnostic-therapeutic pathway from a multidisciplinary perspective
Lung cancer (LC) is the second incident solid tumor and the first cause of cancer-related death worldwide, with more than two million new cases and about 1.800.000 deaths in 2020[1]. In Italy, more than 41.000 new cases have been estimated in 2020 with about 34.000 cancer-related deaths estimated in 2021[2]. Five-year survival rate of LC patients is 15% to 22%, strictly correlated with histological subtype and stage at the diagnosis[1]. Although the detrimental effect of tobacco smoking on incidence and mortality of LC is well established, in Italy smokers amount to more than 14 million people (24.5% of the overall Italian...
Source: Cancer Treatment Reviews - March 16, 2023 Category: Cancer & Oncology Authors: Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo, Andrea Dell'Amore, Elena Scagliori, Mariaenrica Tin è, Fiorella Calabrese, Gaetano Benati, Matteo Sepulcri, Cristina Baiocchi, Michele Milella, Federico Rea, Valentina Guarneri Tags: Hot Topic Source Type: research
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment
Uveal melanoma (UM) is the most common malignant intraocular tumour in adults [1]. As an orphan cancer, UM has a high medical need, which is not met so far. More than half of the patients develop distant metastases during the course of the disease, affecting predominantly the liver. Once distant metastases have occurred, the prognosis is dismal with a median overall survival (mOS) of approximately 1 year across all therapeutic regimens [2]. In contrast to the treatment of metastatic cutaneous melanoma, treatment options including kinase inhibitors, anti-CTLA-4 antibody, and anti-PD-(L)1 antibody were not able to improve th...
Source: Cancer Treatment Reviews - March 13, 2023 Category: Cancer & Oncology Authors: Anne Petzold, Theresa Steeb, Anja Wessely, Elias A.T. Koch, Julio Vera, Carola Berking, Markus V. Heppt Source Type: research
European Expert Panel Consensus on the Clinical Management of BRAFV600E-Mutant Metastatic Colorectal Cancer
Globally, in 2019, colorectal cancer (CRC) resulted in the deaths of 1.09 million people, and there were 2.17 million new cases. [1] In Europe, CRC is the second most diagnosed cancer. Approximately 153,000 people are predicted to die from CRC in 2022.[2,3] About 25% of patients with CRC are diagnosed at the metastatic stage, and 25% of patients with localised disease go on to develop metastases.[4,5] Although the prognosis of patients with metastatic CRC (mCRC) has improved greatly in recent years due to the introduction of more effective chemotherapies, targeted molecular therapies, and immunotherapies, overall survival ...
Source: Cancer Treatment Reviews - March 11, 2023 Category: Cancer & Oncology Authors: Erika Martinelli, Dirk Arnold, Andres Cervantes, Sebastian Stintzing, Eric Van Cutsem, Josep Tabernero, Julien Taieb, Harpreet Wasan, Fortunato Ciardiello Tags: Tumour Review Source Type: research
Comparison of HER2-Zero and HER2-Low in terms of clinicopathological factors and survival in early-stage breast cancer: A Systematic Review and Meta-analysis
Breast cancer (BC) is the most common cancer in women worldwide and the leading cause of cancer mortality in women [1]. BC can be classified into four distinct molecular subtypes according to the expression of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PgR), which are advised as reliable references for precise treatment and prognosis estimation [2]. HER2-positive BC accounts for 15% of whole cases. Although HER2 positivity is known as a poor prognostic feature, it has now been transformed into a predictive advantage thanks to improvements in novel targeted therapy ag...
Source: Cancer Treatment Reviews - March 6, 2023 Category: Cancer & Oncology Authors: Yakup Ergun, Gokhan Ucar, Baran Akagunduz Tags: Systematic or Meta-analysis Studies Source Type: research
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review
Gynecological cancers are a major burden of disease for a significant group of women [1,2]. Disease recurrence is common and platinum resistance is a notable issue for these patients. For example, a substantial group of ovarian cancer (OC) patients have disease recurrence within six months after completion of first line platinum-based chemotherapy [3]. Moreover, durable responses to second line treatments are scarce, although a subset of patients with BRCA1/2-mutated ovarian cancer benefit from PARP-inhibitor treatment [4] and a subgroup of patients with cervical cancer and high PD-L1 expression benefit from immunotherapy ...
Source: Cancer Treatment Reviews - March 2, 2023 Category: Cancer & Oncology Authors: Tim Schutte, Alaa Embaby, Neeltje Steeghs, Stevie van der Mierden, Willemien van Driel, Martin Rijlaarsdam, Alwin Huitema, Frans Opdam Tags: Anti-tumour Treatment Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 1, 2023 Category: Cancer & Oncology Source Type: research
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer mortality worldwide [1,2]. HCC prognosis remains poor, partly because up to 70% of patients are diagnosed with advanced HCC at initial presentation, precluding curative treatments such as resection, liver transplantation (LT) or ablation [3]. Survival outcomes for HCC are better among patients who receive curative rather than non-curative therapies [4]. There is therefore a need to optimize treatment for the majority of patients who undergo non-curative therapy. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 1, 2023 Category: Cancer & Oncology Authors: Jason K Wong, Howard J Lim, Vincent C Tam, Kelly W Burak, Laura A Dawson, Prosanto Chaudhury, Robert J Abraham, Brandon M Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Seged Tags: Anti-tumour Treatment Source Type: research
Optimizing treatment for HER2-positive HR-positive breast cancer
During the last three decades, the human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treatment landscape has changed dramatically [1]. Various anti-HER2 drugs and chemotherapy combinations have been explored in large prospective phase III trials, either in early or advanced settings. HER2 blockade has been maximized with the indication for dual anti-HER2 blockade in early and metastatic HER2-positive BC [2,3]. However, it has also become apparent that HER2-positive BC is a complex disease in view of the heterogeneity of HER2 expression and hormone receptor (HR) expression and their impact on the n...
Source: Cancer Treatment Reviews - February 28, 2023 Category: Cancer & Oncology Authors: Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart Tags: Anti-tumour Treatment Source Type: research
Role of FGFR3 in Bladder Cancer: treatment landscape and future challenges
Bladder cancer (BC) is the 10th most common malignant disease worldwide with a yearly incidence of approximately 573,000 new cases and 212,536 deaths [1]. Men are more likely to develop bladder cancer than women, and disease incidence increases with age [6]. Bladder cancer originates from the transitional epithelium, and urothelial BC is the most common subtype, accounting for more than 90% of cases [7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 27, 2023 Category: Cancer & Oncology Authors: Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, Alberto Servetto, Stefania Belli, Antonio Santaniello, Sarah Scagliarini, Felice Crocetto, Roberto Bianco, Luigi Formisano Source Type: research
